Oncolytic virotherapy as immunotherapy
Open accessAbstract
Recognizing immune responses to oncolytic virotherapy opens the way for new combinations
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oncolytic viruses can lead to induction of an adaptive immune response by releasing tumour and viral antigens from dying cancer cells.
“But, even more important, they can lead to the induction of an adaptive immune response by releasing tumour and viral antigens from dying cancer cells.127”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 16 · Cited by 133
Research works printed but not linked: 2
- [3]Garcia-Carbonero R, J. Immunother. Cancer 5, 71 (2017). 28923104 PMC5604344
- [6]Paz-Ares L N. Engl. J. Med 379, 2040 (2018). 30207915
- Authors
- Melcher, A., Harrington, K., & Vile, R.
- Affiliations
- Institute of Cancer Research (GB)
- Mayo Clinic (US)
- Venue
- Science
- Published
- 2021-12-10
- Volume
- 374
- Issue
- 6573
- Pages
- 1325-1326
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8961675
- OpenAlex
- W4200413360
- Cited by
- 133
- References
- 16
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 36 · 2023: 30 · 2022: 18
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R21CA262994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- oncolytic virotherapy, immunotherapy, combination therapy, tumor immunology
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Combined Modality Therapy, Humans, Immunotherapy, Neoplasms, Randomized Controlled Trials as Topic, Oncolytic Virotherapy, Oncolytic Viruses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
